Figure 2.

Successful adoptive immunotherapy of pulmonary metastases established for 3 days using MVA-LZ primed splenocytes. BALB/c mice were inoculated i.v. with 5×10⁵ CT26.WT or CT26.CL25 (β-gal transfected) tumor cells. Three days later, tumorbearing mice were treated with the adoptive transfer of 2×10⁷ splenocytes obtained from mice primed i.m. with 10⁷ p.f.u. of either MVA or MVA-LZ. 10⁷ p.f.u. of VJS6, delivered i.v., was used as a positive control. Twenty-one days after priming, adoptively transferred splenocytes were cultured in the presence of 10 μg ml⁻¹ of the MHC class I-restricted peptide with the sequence TPHPARIGL, corresponding to residues 876–884 of the full-length β-gal protein, for 6 days before adoptive transfer into tumor bearing mice. Mice were killed 12 days after adoptive transfer of splenocytes, and lung metastases were enumerated in a coded blinded fashion. The experiment was repeated and similar results were obtained